4516 Journal of Medicinal Chemistry, 2006, Vol. 49, No. 15
Smits et al.
purification. Yield 6.19 g (76%). Mp 144-147 °C. 1H NMR
(DMSO-d6) δ (ppm) 10.10 (s, 1H), 9.48 and 9.43 (2s, 1H, rotamers),
8.17-8.05 (m, 1H), 7.94-7.87 (m, 1H), 7.72-7.52 (m, 1H), 7.45-
7.24, (m, 3H), 7.03-6.80 (m, 2H).
(6) Thurmond, R. L.; Desai, P. J.; Dunford, P. J.; Fung-Leung, W. P.;
Hofstra, C. L.; Jiang, W.; Nguyen, S.; Riley, J. P.; Sun, S.; Williams,
K. N.; Edwards, J. P.; Karlsson, L. A potent and selective histamine
H4 receptor antagonist with anti-inflammatory properties. J. Phar-
macol. Exp. Ther. 2004, 309, 404-413.
(7) Takeshita, K.; Bacon, K. B.; Ganter, F. Critical role of L-selectin
and histamine H4 receptor in Zymosan-induced neutrophil recruitment
from the bone marrow: comparison with carrageenan. J. Pharmacol.
Exp. Ther. 2004, 310, 272-280.
(8) Buckland, K. F.; Williams, T. J.; Conroy, D. M. Histamine induces
cytoskeletal changes in human eosinophils via the H(4) receptor. Br.
J. Pharmacol. 2003, 140, 1117-1127.
(9) Ling, P.; Ngo, K.; Nguyen, S.; Thurmond, R. L.; Edwards, J. P.;
Karlsson, L.; Fung-Leung, W. P. Histamine H4 receptor mediates
eosinophil chemotaxis with cell shape change and adhesion molecule
upregulation. Br. J. Pharmacol. 2004, 1, 161-171.
(10) Daugherty, B. L. Histamine H4 antagonism: a therapy for chronic
allergy? Br. J. Pharmacol. 2004, 142, 5-7.
(11) Jablonowski, J. A.; Carruthers, N. I.; Thurmond, R. L. J. A. The
histamine H4 receptor and potential therapeutic uses for H4 ligands.
Mini ReV. Med. Chem. 2004, 4, 993-1000.
(12) Fung-Leung, W. P.; Thurmond, R. L. J. A.; Ling, P.; Karlsson, L.
W. P. Histamine H4 receptor antagonists: the new antihistamines?
Expert Opin. InVest. Drugs 2004, 5, 1174-1183.
(13) de Esch, I. J. P.; Thurmond, R. L. J. A.; Jongejan, A.; Leurs, R. The
histamine H4 receptor as a new therapeutic target for inflammation.
Trends Pharmacol. Sci. 2005, 26, 462-469.
(14) Bell, J. K.; McQueen, D. S.; Rees, J. L. Involvement of histamine
H4 and H1 receptors in scratching induced by histamine receptor
agonists in BalbC mice. Br. J. Pharmacol. 2004, 142, 374-380.
(15) Hagermark, O. Peripheral and central mediators of itch. Skin
Pharmacol. 1992, 5, 1-8.
(16) Lim, H. D.; van Rijn, R. M.; Ling, P.; Bakker, R. A.; Thurmond, R.
L.; Leurs, R. Evaluation of histamine H1-, H2-, and H3-receptor
ligands at the human histamine H4 receptor: Identification of
4-methylhistamine as the first potent and selective histamine H4
receptor agonist. J. Pharmacol. Exp. Ther. 2005, 314, 1310-1321.
(17) Celanire, S.; Wijtmans, M.; Talaga, P.; Leurs, R.; de Esch, I. J. P.
Histamine H3 receptor antagonists reach out for the clinic. Drug
DiscoVery Today 2005, 10, 1613-1627.
Dibenzo[b,f][1,4]oxazepin-11(10H)-one (6b). 2-Fluoro-N-(2-
hydroxyphenyl)-benzamide (5b) (500 mg, 2.16 mmol) was dis-
solved in DMF (10 mL), and one equivalent of freshly powdered
NaOH was added. The resulting mixture was heated at reflux for
5 h After cooling to room temperature, the mixture was diluted
with water (100 mL), and the precipitated product was filtered over
a glass filter and washed with 5% NaOH and then water to remove
the unreacted starting material. The solid residue was dried
overnight under vacuum and was used in the next step without
1
further purification. Yield 320 mg (70%). Mp 210-212 °C. H
NMR (DMSO-d6) δ (ppm) 10.55 (s, 1H), 7.78 (dd, J ) 1.6 Hz, J
) 7.7 Hz, 1H), 7.66-7.58 (m, 1H,), 7.37-7.28 (m, 3H), 7.17-
7.11 (m, 3H).
11-(4-Methylpiperazin-1-yl)-dibenzo[b,f][1,4]oxazepine (7b).
10H-Dibenzo[b,f][1,4]oxazepin-11-one (6b) (1.0 g, 4.7 mmol) was
added to POCl3 (5 mL) and heated at reflux overnight. Excess
POCl3 was evaporated under reduced pressure yielding the crude
iminochloride. Dry toluene (10 mL) and N-methylpiperazine (5.3
mL, 47 mmol) were added to the iminochloride, and the mixture
was heated at reflux. After 2 h, the solvent was allowed to cool to
room temperature, and the mixture was added to EtOAc and water.
The aqueous layer was then extracted with EtOAc, and the
combined organic layers were dried over Na2SO4. Evaporation of
the solvent yielded the crude product, which was purified by flash
chromatography (100% EtOAc) to give the free base as a light
yellow oil. Yield 472 mg (34%); 1H NMR (CDCl3) δ (ppm) 7.45-
6.99 (m, 8H), 3.65 (m, 4H), 2.52 (m, 4H), 2.34 (s, 3H); 13C NMR
(DMSO-d6) δ (ppm) 160.82, 160.20, 152.00, 140.44, 132.45,
129.42, 126,78, 125.36, 124.63, 124.00, 123.48, 121.11, 120.03,
54.84, 47.13, 46.02; MS (ESI) m/z 294 (M + H)+.
(18) Michal, P.; Lysikova, M.; El-Fakahany, E. E.; Tucek, S. Clozapine
interaction with the M2 and M4 subtypes of muscarinic receptors.
Eur. J. Pharmacol. 1999, 376, 119-125.
(19) Zorn, S. H.; Jones, S. B.; Ward, K. M.; Liston, D. R. Clozapine is a
potent and selective muscarinic M4 receptor agonist. Eur. J. Phar-
macol. 1994, 269, R1-R2.
Acknowledgment. We greatly acknowledge Dr. T. Loven-
berg (Johnson & Johnson Pharmaceutical Research and Devel-
opment, L.L.C., San Diego, CA) for the gift of the cells
expressing the human H4R and H3R. Compounds 3, 5, 7, and
13 were generously donated by Dr. Aebischer from the Sandoz
research institute in Bern. Thanks also goes out to Andrea van
de Stolpe for expert technical assistance.
(20) Nagarajan, K.; Kulkarni, L.; Venkateswarlu, A.; Shah, R. Condensed
heterotricycles: Dibenz[b,f][1,4]oxazepin-11(10H)-thiones, 11-
substituted dibenz[b,f][1,4]oxazepines & dibenz[b,f][1,4]thiazepines
analogues. Indian. J. Chem. 1974, 12, 258-262.
(21) Wander, A. Patent DE2316438, 1966.
Supporting Information Available: LCMS purity data for
compounds 7a-n and 14 and experimental details for compounds
5-7a, 7c-f, 14, 5g-n, 6g-n, and 7g-n. This material is available
(22) Bakker, R. A.; Weiner, D. M.; ter Laak, T.; Beuming, T.; Zuiderveld,
O. P.; Edelbroek, M.; Hacksell, U.; Timmerman, H.; Brann, M. R.;
Leurs, R. 8R-lisuride is a potent stereospecific histamine H1-receptor
partial agonist. Mol. Pharmacol. 2004, 65, 538-549.
(23) Liegeois, J. F.; Eyrolles, L.; Ellenbroek, B. A.; Lejeune, C.; Carato,
P.; Bruhwyler, J.; Geczy, J.; Damas, J.; Delarge, J. New pyridoben-
zodiazepine derivatives: modifications of the basic side chain
differentially modulate binding to dopamine (D(4.2), D(2L)) and
serotonin (5-HT(2A)) receptors. J. Med. Chem. 2002, 45, 5136-
5149.
(24) Jablonowski, J. A.; Grice, C. A.; Chai, W.; Dvorak, C. A.; Venable,
J. D.; Kwok, A. K.; Ly, K. S.; Wei, J.; Baker, S. M.; Desai, P. J.;
Jiang, W.; Wilson, S. J.; Thurmond, R. L.; Karlsson, L.; Edwards, J.
P.; Lovenberg, T. W.; Carruthers, N. I. The first potent and selective
nonimidazole human histamine H4 receptor antagonists. J. Med.
Chem. 2003, 19, 3957-3960.
(25) Terzioglu, N.; van Rijn, R. M.; Bakker, R. A.; de Esch, I. J. P.; Leurs,
R. Synthesis and structure-activity relationships of indole- and
benzimidazole piperazines as histamine H4 receptor antagonists.
Bioorg. Med. Chem. Lett. 2004, 14, 5251-5256.
(26) Labute, P.; Williams, C.; Feher, M.; Sourial, E.; Schmidt, J. M.
Flexible Alignment of small molecules. J. Med. Chem. 2001, 44,
1483-1490.
References
(1) Liu, C.; Ma, X.-J.; Jiang, X.; Wilson, S. J.; Hofstra, C. L.; Blevitt,
K.; Li, X.; Chai, W.; Carruthers, N.; Lovenberg, T. W. Cloning and
pharmacological characterization of a fourth histamine receptor (H4)
expressed in bone marrow. Mol. Pharmacol. 2001, 59, 420-426.
(2) Morse, K. L.; Behan, J.; Laz, T. M.; West, R. E., Jr.; Greenfender,
S. A.; Anthes, J. C.; Umland, S.; Wan, Y.; Hipkin, R. W.; Gonsiorek,
W.; Shin, N.; Gustafson, E. L.; Qiao, X.; Wang, S.; Hedrick, J. A.;
Green, J.; Bayne, M.; Monsma, F. J., Jr.; Cloning and characterization
of a novel human histamine receptor. J. Pharmacol. Exp. Ther. 2001,
296, 1058-1066.
(3) Nguyen, T.; Shapiro, D. A.; George, S. R.; Setola, V.; Lee, D. K.;
Cheng, R.; Rauser, L.; Lee, S. P.; Lynch, K. R.; Roth, B. L.; O’Dowd,
B. F. Discovery of a novel member of the histamine receptor family.
Mol. Pharmacol. 2001, 59, 427-433.
(4) Oda, T.; Morikawa, N.; Saito, Y.; Masuho, Y.; Matsumoto, S.
Molecular cloning and characterization of a novel type of histamine
receptor preferentially expressed in leukocytes. J. Biol. Chem. 2000,
275, 36781-36786.
(5) Zhu, Y.; Michalovich, D.; Wu, H.-L.; Tan, K. B.; Dytko, G. M.;
Mannan, I. J.; Boyce, R.; Alston, J.; Tierney, L. A.; Li, X.; Herrity,
N. C.; Vawter, L.; Sarau, H. M.; Ames, R. S.; Davenport, C. M.;
Hieble, J. P.; Wilson, S.; Bergsma, D. J.; Fitzgerald, L. R. Cloning,
expression and pharmacological characterization of a novel human
histamine receptor. Mol. Pharmacol. 2001, 59, 434-444.
(27) Wieland, K.; Bongers, G.; Yamamoto, Y.; Hashimoto, T.; Yama-
todani, A.; Menge, W. M.; Timmerman, H.; Lovenberg, T. W.; Leurs,
R. Constitutive activity of histamine h(3) receptors stably expressed
in SK-N-MC cells: display of agonism and inverse agonism by H(3)
antagonists. J. Pharmacol. Exp. Ther. 2001, 299, 908-914.
JM051008S